Overview of Avomit
| Property | Description |
|---|---|
| Active Ingredient | Letrozole (INN) |
| Form | Oral Tablet (Solid Dosage Form) |
| Pharmacological Class | Aromatase Inhibitor (Third Generation) |
| General Purpose | Systemic Hormonal Control |
| Origin | Synthetic, Nonsteroidal Compound |
Avomit is a prescription-only medication containing the active ingredient Letrozole, which is defined as a non-steroidal aromatase inhibitor and antineoplastic agent. The drug is used for systemic hormonal therapy, a strategy clinically recognized for its role in influencing hormone levels throughout the body. The active compound, Letrozole, is a bis-triazole derivative, a structure that distinguishes its specific and efficient targeting of the aromatase enzyme system.
Defining Avomit: Identity and Pharmacological Class
The core identity of this drug lies in its active component, Letrozole, which is categorized within the class of aromatase inhibitors. Letrozole belongs to the pharmacological group that suppresses estrogen synthesis. This indicates that the medication's primary function is to block the body’s pathway for producing estrogen. As a third-generation inhibitor, Letrozole is specifically recognized for achieving high selectivity in this therapeutic approach.
Composition, Origin, and Dosage Form
Avomit is formulated as a single-active-ingredient product using the synthetic compound Letrozole. This synthetic origin ensures chemical consistency, contrasting with medications derived from natural sources, a standard feature of modern pharmaceuticals. The drug is presented as a solid oral dosage form, specifically an oral tablet for ease of swallowing, establishing its route of administration. The composition necessarily includes the active ingredient alongside various solid oral dosage form excipients, such as binders and fillers, required for the tablet’s stability and controlled absorption.
General Purpose of Aromatase Inhibition
The overarching purpose of this pharmacological class is to provide systemic control over conditions reliant on estrogen for stimulation and progression. The primary function involves estrogen synthesis suppression, where the drug blocks the aromatase enzyme, which is responsible for converting androgen hormones into estrogen in tissues throughout the body. This action significantly reduces the level of circulating estrogen. By removing this significant hormonal stimulus, Avomit serves as a foundational component in strategies requiring hormonal control to stabilize hormone-sensitive processes, particularly in postmenopausal women.
Regulatory References
